Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.07 and traded as low as $0.73. Bolt Biotherapeutics shares last traded at $0.74, with a volume of 71,114 shares changing hands.
Analyst Ratings Changes
Several research analysts have weighed in on the company. Stifel Nicolaus reiterated a “hold” rating and set a $1.50 target price (down from $6.00) on shares of Bolt Biotherapeutics in a report on Wednesday, May 15th. SVB Leerink reiterated a “market perform” rating and issued a $1.00 price objective (down from $3.00) on shares of Bolt Biotherapeutics in a research report on Wednesday, May 15th. HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday, May 15th. Guggenheim reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday, May 15th. Finally, Leerink Partnrs downgraded shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 14th. Five research analysts have rated the stock with a hold rating, According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $3.50.
View Our Latest Research Report on Bolt Biotherapeutics
Bolt Biotherapeutics Stock Performance
Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.23. The business had revenue of $5.27 million for the quarter, compared to analyst estimates of $2.63 million. Bolt Biotherapeutics had a negative net margin of 556.59% and a negative return on equity of 51.74%. As a group, analysts anticipate that Bolt Biotherapeutics, Inc. will post -1.4 EPS for the current fiscal year.
Institutional Trading of Bolt Biotherapeutics
A hedge fund recently raised its stake in Bolt Biotherapeutics stock. Newtyn Management LLC grew its stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) by 2.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,020,000 shares of the company’s stock after purchasing an additional 20,000 shares during the quarter. Newtyn Management LLC owned about 2.69% of Bolt Biotherapeutics worth $1,061,000 at the end of the most recent quarter. 86.70% of the stock is currently owned by hedge funds and other institutional investors.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
Further Reading
- Five stocks we like better than Bolt Biotherapeutics
- ESG Stocks, What Investors Should Know
- The Top 3 Sectors Poised For Growth This Summer
- How to Calculate Return on Investment (ROI)
- U.S. Steel Stock: Betting on EPS Cut and Merger Uncertainty?
- Technology Stocks Explained: Here’s What to Know About Tech
- GitLab Stock: Pioneering the AI-Powered DevSecOps Platform
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.